Effects of SR 49059, an orally active V1a vasopressin receptor antagonist, on vasopressin‐induced uterine contractions

No abstract is available for this paper.

• Publication year

  1997

• Venue

  British Journal of Obstetrics and Gynaecology

• Publication date

  1997-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1471-0528.1997.tb11500.xPMID 9141585
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of the non‐peptide, vasopressin V1a receptor antagonist, SR 49059 and its enantiomer, SR 49770, on isolated human myometrium

  1996cited by this paper
• Receptor‐mediated uterine effects of vasopressin and oxytocin in nonpregnant women

  1995cited by this paper
• Receptors for and myometrial responses to oxytocin and vasopressin in preterm and term human pregnancy: effects of the oxytocin antagonist atosiban.

  1994cited by this paper
• Stimulation of vasopressin release in women with primary dysmenorrhea and after oral contraceptive treatment — Effect on uterine contractility

  1993cited by this paper
• Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.

  1993cited by this paper
• Factors influencing the prevalence and severity of dysmenorrhoea in young women

  1990cited by this paper
• Osmoregulation of vasopressin secretion and thirst during the estrous cycle of pigs.

  1989cited by this paper
• Effects of vasopressin on the human non-pregnant uterus: studies with analogues of different vasopressor potencies.

  1988cited by this paper
• Uterine blood flow and myometrial activity at menstruation, and the action of vasopressin and a synthetic antagonist

  1988cited by this paper
• Can primary dysmenorrhea be alleviated by a vasopressen antagonist?

  1987cited by this paper
• Can primary dysmenorrhea be alleviated by a vasopressin antagonist? Results of a pilot study.

  1987cited by this paper
• Plasma concentrations of vasopressin and a prostaglandin F2 alpha metabolite in women with primary dysmenorrhoea before and during treatment with a combined oral contraceptive.

  1987cited by this paper
• Osmoregulation and control of vasopressin secretion in healthy humans.

  1987cited by this paper
• Vasotocin analogues which competitively inhibit vasopressin stimulated uterine activity in healthy women

  1986cited by this paper
• Vasopressin and Prostaglandins in Premenstrual Pain and Primary Dysmenorrhea

  1984cited by this paper
• Evidence and Quantification of the Vasopressin Arterial Pressure Control System in the Dog

  1980cited by this paper
• PRIMARY DYSMENORRHOEA AND VASOPRESSIN

  1979cited by this paper
• Recording of Myometrial Activity in the Non‐Pregnant Human Uterus by a Micro‐Transducer Catheter

  1978cited by this paper
• EFFECTS OF TERBUTALINE ON MYOMETRIAL ACTIVITY, UTERINE BLOOD FLOW, AND LOWER ABDOMINAL PAIN IN WOMEN WITH PRIMARY DYSMENORRHOEA

  1976cited by this paper

• Primary Dysmenorrhea: pathophysiology

  2021cites this paper
• Vasopressin and Related Peptides; Potential Value in Diagnosis, Prognosis and Treatment of Clinical Disorders.

  2017cites this paper
• Vasopressin V1a and V1b receptors: from molecules to physiological systems.

  2012cites this paper
• In vitro and in vivo pharmacological characterisation of the potent and selective vasopressin V(1A) receptor antagonist 4-[4-(4-Chloro-phenyl)-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl]-piperidin-1-yl-(3,5-difluoro-phenyl) methanone (PF-00738245).

  2011cites this paper
• NON-STEROIDAL ANTI-INFLAMMATORY DRUGS IN THE ALLEVIATION OF PRIMARY DYSMENORRHOEIC PAIN

  2009cites this paper
• Vasopressin antagonists

  2006cites this paper
• Validation of a test model of induced dysmenorrhea

  2006cites this paper
• Intrauterine pressure, ischemia markers, and experienced pain during administration of a vasopressin V1a receptor antagonist in spontaneous and vasopressin‐induced dysmenorrhea

  2006cites this paper
• The effect of relcovaptan (SR 49059), an orally active vasopressin V1a receptor antagonist, on uterine contractions in preterm labor

  2005cites this paper
• ONO‐8815Ly, an EP2 agonist that markedly inhibits uterine contractions in women

  2004cites this paper
• Inhibitory effects of SR 49059 on oxytocin‐and vasopressin‐induced uterine contractions in non‐pregnant women

  2004cites this paper
• The interaction between vasopressin and modulators of the cardiovascular system

  2004cites this paper
• FE 200 440: a selective oxytocin antagonist on the term‐pregnant human uterus

  2003cites this paper
• Vasopressin-induced contraction of uterus is mediated solely by the oxytocin receptor in mice, but not in humans.

  2003cites this paper
• Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.

  2002cites this paper
• Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists

  2001cites this paper
• Oxytocin and its Receptor in the Process of Parturition

  2001cites this paper
• The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists.

  2001cites this paper
• Effect of SR49059, an orally active V1a vasopressin receptor antagonist, in the prevention of dysmenorrhoea

  2000cites this paper
• Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women

  1999cites this paper
• Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects

  1999cites this paper
• Oxytocin and vasopressin constrict rat isolated uterine resistance arteries by activating vasopressin V1A receptors.

  1999cites this paper
• Effects of the nonpeptide V(1) vasopressin receptor antagonist SR49059 in hypertensive patients.

  1999cites this paper
• Evidence for an involvement of vasopressin in mechanism of primary dysmenorrhea and effect of the non-peptide vasopressin V1a receptor antagonist, SR 49059, on the uterus of non-pregnant women.

  1998cites this paper
• Effects of the vasopressin V1a receptor antagonist, SR 49059, on the response of human uterine arteries to vasopressin and other vasoactive substances

  1998cites this paper
• Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists.

  1998cites this paper
• Nonpeptide antagonists for vasopressin receptors. Pharmacology of SR 121463A, a new potent and highly selective V2 receptor antagonist.

  1998cites this paper
• Nonpeptide Antagonists for Vasopressin Receptors

  1998cites this paper
• Contractility in the Nonpregnant Uterus

  1997cites this paper